Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy.
A. Bessudo
No relevant relationships to disclose
J. C. Bendell
No relevant relationships to disclose
N. Gabrail
No relevant relationships to disclose
M. V. Kopp
No relevant relationships to disclose
L. Mueller
No relevant relationships to disclose
L. L. Hart
No relevant relationships to disclose
V. I. Vladimirov
No relevant relationships to disclose
A. U. Pande
Employment or Leadership Position - Daiichi Sankyo
I. Gorbatchevsky
Employment or Leadership Position - Daiichi Sankyo
C. Eng
No relevant relationships to disclose